Schizophrenia Trial, Recruiting NCT06673966 Sponsor: Central South University Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT06673966
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with schizophrenia based on official medical guidelines (called ICD-11 criteria).
  • Your schizophrenia diagnosis has been confirmed using a structured medical interview called the SCID-5-RV.

Who may not be able to join:

  • You have been diagnosed with, or confirmed to have, certain other mental health conditions such as neurodevelopmental disorders (for example, autism or ADHD), bipolar disorder, or drug use disorders — note that alcohol and tobacco use are not included in this exclusion.
  • You currently have a serious or sudden physical illness, such as a brain injury, a brain tumour or brain infection, a severe heart condition, a severe breathing condition, a severe blood disorder, or an autoimmune disease (confirm with trial site for full list).
  • You have been diagnosed with a clearly identified genetic condition, such as tuberous sclerosis, multiple sclerosis, Kleefstra syndrome, 22q11.2 deletion syndrome, Prader-Willi syndrome, or Klinefelter syndrome (confirm with trial site for full list).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86 15874179855

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Central South University
Registry
ClinicalTrials.gov
Start date
10 January 2025
Est. completion
1 February 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change of clinical symptoms by PANSS; Change of the MCCB score; Changes of MRI; Changes of peripheral and central inflammatory factors; Changes of autoantibody; Changes of peripheral immune cells; EEG physiological detection index

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov